We should expect that not every combo study will reach statistical significance.
And so it goes — this time, it was in patients with advanced or recurrent endometrial carcinoma — in a combo with Esai’s latest.
Keytruda is and will remain the world’s highest revenue drug franchise.
Onward, grinning — into a sunny Friday morning….
नमस्ते
Powerline Lies... 